The many faces of interleukin‐17 in inflammatory skin diseases
暂无分享,去创建一个
J. Lambert | S. de Schepper | R. Speeckaert | J. Lambert | L. Grine | M. Van Gele | S. De Schepper | N. Geel | M. Van Gele | R. Speeckaert | N. Geel | L. Grine | M. Gele | S. Schepper
[1] Robert W. Williams,et al. Interleukin 17–producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice , 2008, Nature Immunology.
[2] P. Meroni,et al. Interleukin-17A+ cell counts are increased in systemic sclerosis skin and their number is inversely correlated with the extent of skin involvement. , 2013, Arthritis and rheumatism.
[3] F. Borgia,et al. Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis syndrome (AEDS): association with clinical severity and phenotype. , 2015, Allergy and asthma proceedings.
[4] M. Suárez-Fariñas,et al. A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. , 2016, The Journal of allergy and clinical immunology.
[5] M. Furue,et al. Mutual upregulation of endothelin‐1 and IL‐25 in atopic dermatitis , 2015, Allergy.
[6] A. Bruce,et al. Mast Cells and Neutrophils Release IL-17 through Extracellular Trap Formation in Psoriasis , 2011, The Journal of Immunology.
[7] Thomas Korn,et al. IL-17 and Th17 Cells. , 2009, Annual review of immunology.
[8] Martin M. Schumacher,et al. Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL-17A inhibition in psoriasis , 2015, Experimental dermatology.
[9] T. Naka,et al. Dysregulation of melanocyte function by Th17‐related cytokines: significance of Th17 cell infiltration in autoimmune vitiligo vulgaris , 2012, Pigment cell & melanoma research.
[10] J. Kolls,et al. Targeting IL-17 and TH17 cells in chronic inflammation , 2012, Nature Reviews Drug Discovery.
[11] M. Atwa,et al. T‐helper 17 cytokines (interleukins 17, 21, 22, and 6, and tumor necrosis factor‐α) in patients with alopecia areata: association with clinical type and severity , 2016, International journal of dermatology.
[12] F. Mackay,et al. Clinical associations of serum interleukin-17 in systemic lupus erythematosus , 2013, Arthritis Research & Therapy.
[13] S. Gaffen,et al. IL-17–Mediated Immunity to the Opportunistic Fungal Pathogen Candida albicans , 2015, The Journal of Immunology.
[14] M. Veldhoen,et al. TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. , 2006, Trends in immunology.
[15] J. Ring,et al. Differential in situ expression of IL-17 in skin diseases. , 2012, European journal of dermatology : EJD.
[16] Marc Vandemeulebroecke,et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial , 2012, Gut.
[17] D. Fanoni,et al. Expression of cytokines, chemokines and other effector molecules in two prototypic autoinflammatory skin diseases, pyoderma gangrenosum and Sweet's syndrome , 2014, Clinical and experimental immunology.
[18] A. Fischer,et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis , 2011, The Journal of experimental medicine.
[19] E. Alpsoy,et al. IL-17A has an important role in the acute attacks of Behçet's disease. , 2010, The Journal of investigative dermatology.
[20] M. Tauber,et al. Alopecia areata developing during ustekinumab therapy: report of two cases. , 2013, EJD. European journal of dermatology.
[21] B. Strober,et al. Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis. , 2015, The New England journal of medicine.
[22] M. Suárez-Fariñas,et al. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population. , 2015, The Journal of allergy and clinical immunology.
[23] M. Lebwohl,et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials , 2015, The Lancet.
[24] M. Suárez-Fariñas,et al. Dominant Th1 and minimal Th17 skewing in discoid lupus revealed by transcriptomic comparison with psoriasis , 2013, The Journal of investigative dermatology.
[25] D. Elashoff,et al. Propionibacterium acnes induces an interleukin-17 response in acne vulgaris that is regulated by vitamin A and vitamin D , 2013, The Journal of investigative dermatology.
[26] M. Netea,et al. Compartmentalized Cytokine Responses in Hidradenitis Suppurativa , 2015, PloS one.
[27] A. Gurney,et al. IL‐17: prototype member of an emerging cytokine family , 2002, Journal of leukocyte biology.
[28] T. Giner,et al. Keratinocytes and neutrophils are important sources of proinflammatory molecules in hidradenitis suppurativa , 2016, The British journal of dermatology.
[29] G. Seymour,et al. Regulation of immune cells in oral lichen planus , 2015, Archives of Dermatological Research.
[30] Zengtong Zhou,et al. Expression of Foxp3 and interleukin-17 in lichen planus lesions with emphasis on difference in oral and cutaneous variants , 2014, Archives of Dermatological Research.
[31] T. Buhl,et al. Molecular and Morphological Characterization of Inflammatory Infiltrate in Rosacea Reveals Activation of Th1/Th17 Pathways. , 2015, The Journal of investigative dermatology.
[32] Annette Lee,et al. Genome-wide association study in alopecia areata implicates both innate and adaptive immunity , 2010, Nature.
[33] G. Firestein,et al. Role of Interleukin 17 in Arthritis Chronicity through Survival of Synoviocytes via Regulation of Synoviolin Expression , 2010, PloS one.
[34] F. Mantelli,et al. T-helper 17 lymphocytes in ocular cicatricial pemphigoid , 2009, Molecular vision.
[35] T. Dainichi,et al. Lesional Th17 cells and regulatory T cells in bullous pemphigoid , 2011, Experimental dermatology.
[36] O. Shaker,et al. Role of interleukin‐17 in the pathogenesis of vitiligo , 2011, Clinical and experimental dermatology.
[37] Marziyeh Aghazadeh,et al. Serum Level of Interleukin 17 in Patients with Erosive and Non erosive Oral Lichen Planus , 2013, Journal of dental research, dental clinics, dental prospects.
[38] J. Colombel,et al. Secukinumab failure in Crohn's disease: the yeast connection? , 2012, Gut.
[39] A. Georgescu,et al. IL-17 in cutaneous lupus erythematosus. , 2010, European journal of internal medicine.
[40] A. Paller,et al. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)(+) TH2/TH1 cell imbalance, whereas adults acquire CLA(+) TH22/TC22 cell subsets. , 2015, The Journal of allergy and clinical immunology.
[41] A. Kijlstra,et al. Upregulated IL-23 and IL-17 in Behçet patients with active uveitis. , 2008, Investigative ophthalmology & visual science.
[42] Feng Xu,et al. Imbalance of T‐helper 17 and regulatory T cells in patients with alopecia areata , 2015, The Journal of dermatology.
[43] S. Mehrotra,et al. The Inducible Costimulator Augments Tc17 Cell Responses to Self and Tumor Tissue , 2015, The Journal of Immunology.
[44] Hee-Ryung Cho,et al. Association between IL17A/IL17RA Gene Polymorphisms and Susceptibility to Alopecia Areata in the Korean Population , 2012, Annals of dermatology.
[45] S. Gaffen. Structure and signalling in the IL-17 receptor family , 2009, Nature Reviews Immunology.
[46] I. Bekeredjian-Ding,et al. The Innate Immune Response Against Staphylococcus aureus. , 2015, Current topics in microbiology and immunology.
[47] Jiyao Li,et al. Analysis of oral microbial community and Th17‐associated cytokines in saliva of patients with oral lichen planus , 2015, Microbiology and immunology.
[48] L. Rashed,et al. T helper 17 and Tregs: a novel proposed mechanism for NB‐UVB in vitiligo , 2014, Experimental dermatology.
[49] S. Androudi,et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. , 2013, Ophthalmology.
[50] 古賀 千律子. Possible pathogenic role of Th17 cells for atopic dermatitis , 2011 .
[51] D. Greco,et al. IL-17/Th17 Pathway Is Activated in Acne Lesions , 2014, PloS one.
[52] K. Ley,et al. Homeostatic Regulation of Blood Neutrophil Counts , 2008, The Journal of Immunology.
[53] M. Fujimoto,et al. Impaired IL-17 Signaling Pathway Contributes to the Increased Collagen Expression in Scleroderma Fibroblasts , 2012, The Journal of Immunology.
[54] M. Rosenblum,et al. An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. , 2014, Journal of the American Academy of Dermatology.
[55] B. Elewski,et al. Secukinumab in plaque psoriasis--results of two phase 3 trials. , 2014, The New England journal of medicine.
[56] O. Shaker,et al. Possible role of interleukin‐17 in the pathogenesis of lichen planus , 2012, The British journal of dermatology.
[57] A. Khamesipour,et al. The effect of conventional immunosuppressive therapy on cytokine serum levels in pemphigus vulgaris patients. , 2014, Iranian journal of allergy, asthma, and immunology.
[58] Kathleen M. Smith,et al. Development, cytokine profile and function of human interleukin 17–producing helper T cells , 2007, Nature Immunology.
[59] Lai Wei,et al. IL-21 Is Produced by Th17 Cells and Drives IL-17 Production in a STAT3-dependent Manner* , 2007, Journal of Biological Chemistry.
[60] G. Pier,et al. Topical Neutralization of Interleukin-17 during Experimental Pseudomonas aeruginosa Corneal Infection Promotes Bacterial Clearance and Reduces Pathology , 2012, Infection and Immunity.
[61] A. Gottlieb,et al. Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial , 2015, The Lancet.
[62] Xinyang Song,et al. The activation and regulation of IL-17 receptor mediated signaling. , 2013, Cytokine.
[63] C. Terao,et al. Neutrophils Are Essential As A Source Of Il-17 In The Effector Phase Of Arthritis , 2013, PloS one.
[64] Alpana Sharma,et al. Circulatory levels of T-cell cytokines (interleukin [IL]-2, IL-4, IL-17, and transforming growth factor-β) in patients with vitiligo. , 2012, Journal of the American Academy of Dermatology.
[65] Lisa C. Zaba,et al. Th17 cytokines interleukin (IL)‐17 and IL‐22 modulate distinct inflammatory and keratinocyte‐response pathways , 2008, The British journal of dermatology.
[66] C. Vestergaard,et al. IL-25 in atopic dermatitis: a possible link between inflammation and skin barrier dysfunction? , 2011, The Journal of investigative dermatology.
[67] M. Lebwohl,et al. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing. , 2015, The Journal of allergy and clinical immunology.
[68] T. Wynn,et al. Fibrosis is regulated by Th2 and Th17 responses and by dynamic interactions between fibroblasts and macrophages. , 2011, American journal of physiology. Gastrointestinal and liver physiology.
[69] J. Carucci,et al. Low Expression of the IL-23/Th17 Pathway in Atopic Dermatitis Compared to Psoriasis1 , 2008, The Journal of Immunology.
[70] M. Schaller,et al. Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. , 2011, Archives of dermatology.
[71] C. Weaver,et al. Neutrophils Produce Interleukin 17A (IL-17A) in a Dectin-1- and IL-23-Dependent Manner during Invasive Fungal Infection , 2011, Infection and Immunity.
[72] Massimo Gadina,et al. Jakpot! New small molecules in autoimmune and inflammatory diseases , 2014, Experimental dermatology.
[73] V. Engelhard,et al. Immune responses in a mouse model of vitiligo with spontaneous epidermal de‐ and repigmentation , 2014, Pigment cell & melanoma research.
[74] S. Batra,et al. IFN-γ induction by neutrophil-derived IL-17A homodimer augments pulmonary antibacterial defense , 2015, Mucosal Immunology.
[75] E. Barillot,et al. A critical function for transforming growth factor-β, interleukin 23 and proinflammatory cytokines in driving and modulating human TH-17 responses , 2008, Nature Immunology.
[76] R. Hegazy,et al. Interleukin 17, interleukin 22 and FoxP3 expression in tissue and serum of non-segmental vitiligo: a case- controlled study on eighty-four patients. , 2013, European journal of dermatology : EJD.